U.S. Markets closed

Analyzing Pfizer’s Ibrance and Xalkori after 2Q17

Daniel Collins
Analyzing Pfizer’s Ibrance and Xalkori after 2Q17

In 4Q17, Pfizer’s (PFE) Ibrance generated revenues of $716 million, which reflected ~11% growth on a YoY (year-over-year) basis and an 18% decline quarter-over-quarter. In the US market in 4Q17, Ibrance generated revenues of $777 million, which reflected ~27% growth on a YoY basis. In emerging markets in 4Q17, Ibrance reported revenues of $49 million—compared to $17 million in 4Q17.